All Updates

All Updates

icon
Filter
Funding
Rapport biotherapeutics raises USD 150 million in Series B funding
Precision Medicine
Aug 23, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Aug 23, 2023

Rapport biotherapeutics raises USD 150 million in Series B funding

Funding

  • Clinical-stage biotechnology company Rapport Therapeutics has raised USD 150 million in a Series B funding round led by Cormorant Asset Management, with participation from new investors including Fidelity Management & Research Company, Goldman Sachs Asset Management, and T. Rowe Price Associates, Inc., as well as all existing investors, including Third Rock Ventures, ARCH Venture Partners, and Johnson & Johnson Innovation - JJDC, Inc. (JJDC).

  • The funding will support the advancement of Rapport's pipeline of precision neurology drugs, including progressing current clinical programs for seizures and psychiatric conditions, as well as expanding into new indications using its receptor-targeting platform.

  • In conjunction with the financing, the company has elected two new boards of directors to advance the precision neuro medicine platform. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.